Epigenetic editing to advance CAR T cell therapy - PubMed
4 hours ago
- #Epigenetics
- #CAR-T
- #CRISPR
- CAR T cell therapy has revolutionized cancer treatment by targeting tumor cells selectively.
- Despite its success in haematological cancers, 40-60% of patients do not achieve a durable response.
- Solid tumors present challenges like limited T cell infiltration and an immunosuppressive microenvironment.
- Epigenetic modifications play a critical role in T cell activation, memory formation, and exhaustion.
- Disrupting epigenetic regulators like TET2 or DNMT3A can enhance CAR T cell memory and antitumor activity.
- Epigenetic editing offers precise, durable, and reversible gene expression reprogramming without DNA breaks.
- Targeted silencing of inhibitory receptors like PD-1 and LAG-3 can improve CAR T cell phenotypes.
- Epigenetic editing can also enable off-the-shelf CAR T cells by silencing immune rejection pathways.
- This review explores how epigenetic strategies can enhance CAR T cell potency, persistence, and accessibility.